Aspects of drug toxicity
Iatrogenic disease has arisen from the extensive usage of the broad range of modern drugs available today. Drug toxicity, however, may be minimized by the exercise of greater discretion in the use of drugs, which are only an adjunct in the improvement of community health. Although better medical care has led to an increase in the expectation of life, this has brought with it problems of drug toxicity peculiar to an ever-increasing population of geriatric patients. Similarly, the probability of side effects in a given course of treatment has increased as drug therapy is offered to this diverse community of the 20th century. Factors causing abnormal metabolism, such as age, genetic variation, diet and drug formulation, were discussed at the postgraduate school on 'Aspects of Drug Toxicity' held at Chelsea College, London, in April 1978. The postgraduate school, organized jointly by the Department of Pharmacy, Chelsea College and the Pharmaceutical Society of Great Britain, was led by Mr J W Gorrod (Chelsea College, London) and consisted of lectures from many distinguished scientists, practical classes and demonstrations. Professor A H Beckett (Chelsea College, London) outlined 'course aims and contents' and the lectures were begun by Mr J W Gorrod, who discussed toxic products produced during the metabolism of drugs and foreign compounds, e.g. epoxides, hydroxylamines and hydroxamic acids. Because of their chemical reactivity, these metabolites are able to interact with cellular organelles and constituents, thus producing toxic effects.
Professor T F Slater (Brunei University, Uxbridge) continued with the theme of hepatotoxic effects caused by various compounds, such as carbon tetrachloride and amines, and he discussed free radical intermediates produced in the liver by the activation of these compounds; examples of these include trichloromethyl and nitroxyl radicals, which bind to proteins and nucleotides.
The toxicological consequences of enzyme induction and inhibition by polycyclic hydrocarbons, steroids and other drugs were discussed by Professor D V Parke (University of Surrey).
Increase in drug toxicity may accompany both inhibition of detoxication pathways and induction of metabolic pathways which produce toxic metabolites.
The influence of age on the metabolism and toxicity of drugs was considered by Dr W R Examples of drugs cited by Dr Felix included steroids and antihistamines. Related problems of differential diagnosis were also discussed.
Toxic effects of compounds on the pulmonary system were described by Dr M Orme (University of Liverpool). Illustrations of various immunological mechanisms involved in drug allergies were included.
Professor R H Girdwood (University of Edinburgh) considered the effects of drugs and their metabolites on blood and blood-forming systems. The occurrence of aplastic anaemia, leukopenia or thrombocytopenia following therapy with a variety of non-narcotic analgesics is particularly troublesome and little understood.
Dr C I Levene (University of Cambridge) described osteolathyrism, a disease of the connective tissue, which is produced by the 'lathyrus factor', {i-amino propionitrile (BAPN). It has been shown that BAPN can inhibit fibrosis chemotherapeutically; this toxic reaction has been shown to be advantageous in the treatment of pulmonary silicosis in rats. It is hoped that further work will lead to a compound having a therapeutic effect in man in decreasing deleterious fibrosis.
Professor F Beck (University of Leicester) discussed teratogenesis produced by drugs and related compounds and stressed the dangers existing in the use of rigid, unvarying test systems. The production of neoplasia during drug therapy was described by Professor T A Connors (MRC Toxicology Unit, Carshalton). The metabolic production of reactive species important in iatrogenic cancer was discussed together with recent evidence which suggests that patients treated with certain cytotoxic agents have an increased probability of developing neoplasia.
The series of lectures concluded with a paper by Dr D H Keeling (Plymouth General Hospital), who discussed the many side effects associated with the use of radiopharmaceuticals and emphasized the need for stricter control in the handling and production of reactive sources used in radiotherapy.
Attendance at this school by scientists from all over the United Kingdom and Europe gives an indication of the mounting interest in problems of drug toxicity. The lectures are being published early in 1979 (Aspects of Drug Toxicity, edited by J W Gorrod. Taylor & Francis, London).
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Cancer chemotherapy: successes, failures and hopes
Successes, failures and hopes in cancer chemotherapy was the theme of an international symposium 1 organized by the Medico-Pharmaceutical Forum at the end of May 1978. In opening the Symposium Professor G Mathe (Paris) spoke of the alternating moods of optimism and pessimism which have characterized work in the cancer field. The need was to maintain the momentum of recent years and the symposium aimed to bring together academic and pharmaceutical interests, to review what had been achieved and to rook at some of the new developments.
To put the present place of chemotherapy into perspective Professor N M Bleehen (Cambridge) emphasized what, by unwritten Transatlantic agreement, has come to be known as the multimodality approach. It is the simple common sense of using surgery, radiotherapy and chemotherapy together to achieve the best total effect. In looking to the future it is appropriate to keep the door open for developments in immunology, dietary manipulation, hyperthermia and unconventional methods, provided they can be demonstrated to be unequivocally effective.
Surgery is generally considered to be fully exploited but the question how much further radiotherapy can be extended presents an interesting challenge through the development of radiosensitizing drugs which have a powerful electron affinity and exert their main effects on radioresistant hypoxic cells. Dr K E Halnan (Glasgow) reviewed this development and preliminary clinical studies are beginning to appear, but it is still too 1 Report to be published (spring 1979) by the Forum, 1 WimpoleStreet, London, WI M 8AE 01410768/79/020152 .()2/$01.000 early to assess the potential of even the first drugs available for clinical trial.
Professor H G Schwick (Marburg) outlined the difficulties encountered in attempting to manipulate host immunological activity, but we are further on the road to understanding these problems now than we were a few years ago, when numerous attempts were being made to translate inadequate immunological knowledge into immunotherapeutic procedures; it seems clear that the prospects for successful immunological manipulation depend on unravelling the highly complex mechanisms involved.
The fact that chemotherapy is so far effective for only a small range of malignancies is partly compensated by the fact that sensitive tumours occur predominantly in young adults and children.
Professor J M A Whitehouse (Southampton) reviewed their main area of impact, the acute lymphoblastic leukaemias and Hodgkin's disease, together with their less prolonged benefits for patients with the acute myeloblastic leukaemias and non-Hodgkin's lymphoma. Although children's cancer accounts for only I~o of all tumours, cancer now comes second only to accidents as a cause of death in childhood. The treatment of Wilms' tumour, rhabdomyosarcoma and some brain tumours by multiple modality approach is one of the areas of success and Dr J S Malpas (St Bartholomew's Hospital) drew attention to the need to have drugs which could be used without long-term toxicity on heart, lungs, liver and kidneys, and which did not incur the risk of second primary tumours.
In the adult solid tumour field reviewed by Dr E S Newlands (Charing Cross Hospital) the major successes had been few, although temporary con-
